Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLS-6150 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost) |
| Group 2 | EXPERIMENTAL | GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost) |
| Group 3 | EXPERIMENTAL | GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost) |
| Group 4 | EXPERIMENTAL | GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost) |
| Name | Type | Description |
|---|---|---|
| GLS-6150 | BIOLOGICAL | Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection) |
Inclusion Criteria: 1. Age 19-65 years; 2. HCV seronegative (Group 1 only), HCV seropositive (Groups 2, 3, 4 only) 3. Prior treatment for genotype 1a or 1b Hepatitis C infection with treatment ending (12 weeks after end of DAA treatment, 24 weeks after end of combination treatment with Ribavirin/In...
Top 20 of 28 competitors
GLS-6150 is an investigational monoclonal antibody being developed for the treatment of HCV Infection, a viral infection of the liver. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GLS-6150 is being developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol INO. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational drug.
GLS-6150 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 1 trial has been completed, and the drug remains under clinical investigation for HCV Infection.
GLS-6150 has one completed Phase 1 clinical trial, identified as NCT03674125. This study evaluated the safety, tolerability, and immunogenicity of GLS-6150 in healthy volunteers and in persons previously treated for Hepatitis C Virus infection. The trial enrolled 32 participants in South Korea.
GLS-6150 is a distinct investigational monoclonal antibody developed by Inovio Pharmaceuticals. No alternative names for this drug have been disclosed in the clinical trial information. It is being studied specifically for its potential role in treating HCV Infection.